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A B S T R A C T
Pregnant women diagnosed with gestational diabetes mellitus subjected to diet (GDMd) that do not reach normal
glycaemia are passed to insulin therapy (GDMi). GDMd associates with increased human cationic amino acid
transporter 1 (hCAT-1)-mediated transport of L-arginine and nitric oxide synthase (NOS) activity in foetopla-
cental vasculature, a phenomenon reversed by exogenous insulin. Whether insulin therapy results in reversal of
the GDMd eﬀect on the foetoplacental vasculature is unknown. We assayed whether insulin therapy normalizes
GDMd-associated foetoplacental endothelial dysfunction. Primary cultures of human umbilical vein endothelial
cells (HUVECs) from GDMi pregnancies were used to assay L-arginine transport kinetics, NOS activity, p44/
42mapk and protein kinase B/Akt activation, and umbilical vein rings reactivity. HUVECs from GDMi or GDMd
show increased hCAT-1 expression and maximal transport capacity, NOS activity, and eNOS, and p44/42mapk,
but not Akt activator phosphorylation. Dilation in response to insulin or calcitonin-gene related peptide was
impaired in umbilical vein rings from GDMi and GDMd pregnancies. Incubation of HUVECs in vitro with insulin
(1 nmol/L) restored hCAT-1 and eNOS expression and activity, and eNOS and p44/42mapk activator phos-
phorylation. Thus, maternal insulin therapy does not seem to reverse GDMd-associated alterations in human
foetoplacental vasculature.
1. Introduction
Gestational diabetes mellitus (GDM) is a disease of pregnancy that
characterizes by abnormal maternal D-glucose metabolism and altered
insulin signalling in the foetoplacental circulation [1–5]. GDM-asso-
ciated alterations lead to foetal hyperglycaemia and hyperinsulinemia
resulting in endothelial dysfunction, and abnormal placental develop-
ment and foetal growth [5,6]. Pregnant women that develop GDM are
subjected to controlled diet (GDMd pregnancies) to reduce glycaemia to
the recommended goals [1,4,7]. However, a fraction of these women
does not reach normal glycaemia with diet and are passed to treatment
with insulin (i.e., insulin therapy, GDMi pregnancies) until delivery
[3,4,8–10]. Both the mother and newborns in GDMd and GDMi preg-
nancies show with normal glycaemia at term [11–13]. However, the
foetoplacental endothelial cell function and vascular reactivity are al-
tered in GDMd [3,5,13].
Increased expression and activity of the endothelial nitric oxide
synthase (eNOS) and uptake of the amino acid L-arginine via the human
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cationic amino acid transporter 1 (hCAT-1), an isoform of human ca-
tionic amino acids transporters (hCATs) family [14,15], is reported in
human umbilical vein endothelial cells (HUVECs) from GDMd preg-
nancies [13,16]. Exposure of HUVECs in vitro to physiological con-
centrations of insulin (up to 1 nmol/L) reverses the eﬀects of GDMd on
L-arginine transport [13] and NO synthesis [16]. Interestingly, high
extracellular D-glucose (~25 mmol/L) also increases L-arginine trans-
port via hCAT-1 and NO synthesis in HUVECs from normal pregnancies
suggesting that hyperglycaemia could cause these changes in en-
dothelial function [17]. Since insulin therapy results in normalization
of the glycaemia in the mother and newborn at birth [4,9,18,19], a
reversal of the eﬀects of GDMd in the foetoplacental endothelial func-
tion is likely. In this study, we assayed whether maternal insulin
therapy reverses the eﬀects seen in GDMd on HUVECs function at birth.
The results suggest that insulin therapy is not enough to reverse the
foetoplacental endothelial dysfunction seen at birth in normoglycaemic,
diet-controlled women with GDM.
2. Material and methods
2.1. Antibodies and materials
Primary monoclonal mouse anti-hCAT-1 and anti-ß-actin antibodies
were from Sigma Aldrich (St Louis, MO, USA). Primary monoclonal
mouse anti-eNOS phosphorylated at serine1177, polyclonal rabbit anti-
total p44/42mapk, anti-phosphorylated p44/42mapk, anti-total Akt and
anti-phosphorylated Akt antibodies were from Cell Signaling
Technology (Danvers, MA, USA). Primary monoclonal mouse anti-eNOS
phosphorylated at threonine495 antibody was from BD Transduction
Laboratories (San Jose, CA, USA). Primary monoclonal mouse anti-total
eNOS antibody and secondary horseradish peroxidase-conjugated goat
anti-rabbit or anti-mouse antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). For isolation of HUVECs from
umbilical cords Collagenase Type II from Clostridium histolyticum
(Boehringer, Mannheim, FRG) was used. Medium M199, new born
(NBCS) and fetal calf (FCS) sera, L-glutamine, and penicillin-strepto-
mycin were from Gibco Life Technologies (Carlsbad, CA, USA). L-
[3H]Arginine and D-[3H]mannitol were from NEN (Dreieich, FRG). NG-
Nitro-L-arginine methyl ester (L-NAME) and calcitonine gene related
peptide (CGRP) were from Sigma Aldrich, and Akt Inhibitor IV (Inh-IV)
and PD-98059 from Calbiochem (La Jolla, CA, USA). Immobilon-P
polyvinylidene diﬂuoride membranes was from BioRad Laboratories
(Hertfordshire, UK). Qiagen RNAeasy kit was from Qiagen (Crawley,
UK) and brilliant SYBR green qPCR Master Mix from Stratagene (La
Jolla, CA, USA). The ﬂuorescent dye 4-amino-5-methylamino-2′,7′-di-
ﬂuoroﬂuorescein (DAF-FM) was from Molecular Probes (Leiden, The
Netherlands).
2.2. Study groups
This study included samples collected from 13 full-term normal or
32 full-term GDM pregnancies from the Hospital Clínico UC-CHRISTUS
(HCUC-C) and Hospital San Juan de Dios (HSJD) in Santiago de Chile.
Pregnant women included in this study did not smoke or consume drugs
or alcohol, and had no intrauterine infection or any other medical or
obstetrical complications. Ethnicity of patients included in this study
was Hispanic. The investigation conforms to the principles outlined in
the Declaration of Helsinki. Ethics Committee approvals from the
Faculty of Medicine of the Pontiﬁcia Universidad Católica de Chile and
HSJD, and informed written consent of patients were obtained. All
pregnant women with a normal glycaemia at the ﬁrst trimester of
pregnancy were evaluated by an oral glucose tolerance test (OGTT)
with a unique glucose load (75 g fasting) at 24–28 weeks of gestation.
Patients with basal glycaemia ≥5.56 (≥100 mg/dL, 8-9 h from last
feeding in at least two diﬀerent days) and with ≥7.9 mmol/L
(≥140 mg/dL) at 2 h after glucose load at the second or third trimester
of pregnancy were diagnosed with GDM (according to the Perinatal
Guide 2015 report from the Health Ministry of Chile) [20]. Weight and
body mass index (BMI) were recorded before pregnancy (i.e., pre-ge-
stational) and for each trimester of pregnancy and at term.
Three groups of pregnant women were included in this study, i.e.,
normal pregnancies (n = 13), GDMd pregnancies (n= 14), or GDMd
pregnancies where the mother was treated with insulin (GDMi, i.e., on
insulin therapy) (n= 18). Qualiﬁed personnel of the HCUC-C and HSJD
selected the groups of pregnant women according to their clinical
characteristics following established protocols. Women coursing with
normal pregnancies followed standard self-controlled diet and physical
activity. Women with GDMd were subjected to dietary treatment with
1500 kcal/day and a maximum of 200 g per day carbohydrates. Plasma
glucose was weekly measured at fasting and post-breakfast, before and
1 h after the midday and evening meals. Women with GDMd that did
not reach normal glycaemia after two weeks of diet were passed into
insulin therapy following protocols adopted at the Division of
Obstetrics and Gynaecology at the HCUC-C and HSJD as recommended
in the Perinatal Guide 2015 Chile [20]. In brief, women with GDMd not
responsive to diet were treated for 8–10 weeks until delivery with two
injections (one before breakfast and one at bedtime) of neutral prota-
mine Hagerdon human insulin (Humulin-N or Insuman-N,
0.5–0.65 units/kg of pre-pregnancy body weight). Additional three in-
jections of regular (rapid-acting) insulin (Humulin-R or Insuman-R)
depending on pre-prandial self-controlled capillary glycaemia (0.1 to
6 units/kg per meal for 81–120 to> 250 mg/dL glucose, respectively)
were administered to women with GDMd as described for insulin
therapy in pregnant women with pre-gestational diabetes mellitus type
1 or 2 [11,21].
2.3. Human placenta and umbilical cords
Placentas were collected at delivery on ice and transferred to the
laboratory until use 15–30 min later. Middle sections of umbilical cords
(100–120 mm length) were dissected into 200 mL phosphate-buﬀered
saline (PBS) solution (mmol/L: 130 NaCl, 2.7 KCl, 0.8 Na2HPO4, 1.4
KH2PO4, pH 7.4, 4 °C) until use 6–12 h later for isolation of endothelial
cells.
2.4. Cell culture
HUVECs were isolated by collagenase digestion (0.25 mg/mL col-
lagenase) from umbilical cords obtained at birth from normal, GDMd,
or GDMi pregnancies and cultured (37 °C, 5% CO2) in 1% gelatin-
coated petri dishes (100 mm diameter) up to passage 3 in primary
culture medium (PCM; M199 containing 5 mmol/L D-glucose, 10%
NBCS, 10% FCS, 3.2 mmol/L L-glutamine and 100 U/mL penicillin-
streptomycin). 16 h prior experiments the incubation medium was
changed to M199 medium containing 0.25% NBCS and 0.25% FCS.
Experiments were performed in the absence (hereafter referred as
‘without insulin’) or presence (8 h, hereafter referred as ‘with insulin’)
of insulin (1 nmol/L), L-NAME (100 μmol/L, NOS inhibitor) [22], Inh-
IV (1 μmol/L, protein kinase B/Akt inhibitor) [23], and/or PD-98059
(10 μmol/L, MAP kinase kinases 1/2 inhibitor) [24].
2.5. L-Arginine transport
Overall 0–1000 μmol/L L-arginine transport (3 μCi/mL L-[3H]argi-
nine, 1 min incubation, 37 °C) was measured in Krebs solution (mmol/
L: 131 NaCl, 5.6 KCl, 25 NaHCO3, 1 NaH2PO4, 20 Hepes, 2.5 CaCl2, 1
MgCl2, pH 7.4, 37 °C) as described [13]. Overall transport of L-arginine
was deﬁned as the result of the sum of a saturable component plus a
nonsaturable, linear component of transport in the range of L-arginine
concentrations used in this study (hereafter referred as a KD value de-
ﬁned by m · [Arg], where m corresponds to slopes of lineal phases of
transport at a given L-arginine concentration [Arg]) [13]. Cell
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monolayers were rinsed with ice-cold Krebs to terminate tracer uptake.
Initial rate for transport (i.e., linear uptake up to 1 min) was derived
from the slope of the linear phases of L-arginine transport. Values for
transport were adjusted to the one phase exponential association
equation considering the least squares ﬁt:
= ∙ −
− ∙v V e(1 )i m k t( )
where vi is initial velocity, Vm is mayor velocity at a given time (t) and L-
arginine concentration, and e and k are constants. Overall L-arginine
transport at initial rates was adjusted to the Michaelis-Menten hy-
perbola plus a nonsaturable, linear component (KD) as described [13].
The saturable transport of L-arginine was derived by subtracting the
m · [Arg] components from overall transport, and the transport kinetic
parameters maximal velocity (Vmax) and apparent Michaelis-Menten
constant (Km) of transport were calculated [13]. The relative con-
tribution of GDMd, GDMi, insulin, PD-98059, or Inh-IV to the saturable
L-arginine transport kinetic parameters was estimated from the maximal
transport capacity (Vmax/Km) values for L-arginine transport by:
=
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where CVmax and CKm are the kinetics parameters for L-arginine trans-
port in control conditions (i.e., in the absence of insulin, PD-98059, or
Inh-IV) in cells from normal, GDMd, or GDMi pregnancies, and XVmax
and XKm are kinetics parameters of L-arginine transport in HUVECs from
normal, GDMd, or GDMi pregnancies exposed to diﬀerent experimental
conditions [13,25]. Each transport assay was run in duplicate with
transport activity expressed as pmol/μg protein/minute. Radioactivity
in 0.5 N KCl cell digests was determined by liquid scintillation
counting, and uptake was corrected for D-[3H]mannitol disintegrations
per minute (d.p.m.) in the extracellular space [13].
2.6. Western blotting
Total protein was obtained from conﬂuent cells washed twice with
ice-cold PBS and harvested in 100 μL of lysis buﬀer composed by
63.7 mmol/L Tris/HCl (pH 6.8), 10% glycerol, 2% sodium dode-
cylsulphate (SDS), 1 mmol/L sodium orthovanadate, 50 mg/mL leu-
peptin, and 5% 2-mercaptoethanol, as described [13]. Cells were so-
nicated (6 cycles, 5 s, 100 W, 4 °C), and total protein was separated by
centrifugation (14,000g, 15 min, 4 °C). Proteins (70 μg) were separated
by polyacrylamide gel (10%) electrophoresis and transferred onto Im-
mobilon-P polyvinylidene diﬂuoride membranes. The proteins were
then probed against hCAT-1 (1:500 dilution, 12 h, 4 °C), total eNOS
(1:500 dilution, 12 h, 4 °C), eNOS phosphorylated at serine1177
(P~Ser1177-eNOS, 1:1000 dilution, 12 h, 4 °C), eNOS phosphorylated at
threonine495 (P~Thr495-eNOS, 1:1000 dilution, 12 h, 4 °C), total p44/
42mapk (1:1000 dilution, 3 h, room temperature), phosphorylated p44/
42mapk (1:1000 dilution, 3 h, room temperature), total Akt (1:1000
dilution, 3 h, room temperature), phosphorylated Akt (1:1000 dilution,
3 h, room temperature), and β-actin (1:3000, 1 h, room temperature).
Membranes were rinsed in Tris buﬀer saline Tween and incubated (1 h)
in TBS-T/0.2% BSA containing secondary horseradish peroxidase-con-
jugated antibodies. Proteins were detected by enhanced chemilumi-
nescence (ﬁlm exposure time was 1 min) in a ChemiDoc-It 510 Imagen
System (UVP, LCC Upland, CA, USA) and quantiﬁed by densitometry
[13].
2.7. Isolation of total RNA and reverse transcription
Total RNA was isolated using the Qiagen RNAeasy kit. RNA quality
and integrity were insured by gel visualization and spectrophotometric
analysis (OD260/280), quantiﬁed at 260 nm. Aliquots (2 μg) of total RNA
were reversed transcribed into cDNA as described [13].
2.8. Quantitative RT-PCR
Experiments were performed using a StepOne Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA) in a reaction mix
containing 0.5 μmol/L primers, and master mix provided in the brilliant
SYBR green qPCR Master Mix as described [13]. SecureStartTaq DNA
polymerase was activated (15 min, 95 °C), and the PCR cycling proﬁle
included a 95 °C denaturation (15 s), annealing (20 s) at 54 °C (hCAT-1
and 28S) or 60 °C (eNOS, insulin receptor A (IR-A), insulin receptor B
(IR-B)), and extension at 72 °C for variable times (hCAT-1, 10 sec;
eNOS, 17 sec; IR-A and IR-B, 20 sec; 28S, 10 s). Product melting tem-
perature values were 79.1 °C (hCAT-1), 86.43 °C (eNOS), 87.2 °C (IR-
A), 87.6 °C (IR-B), and 86.7 °C (28S). The oligonucleotide primers used
in this study were: hCAT-1 sense: 5′-GAGTTAGATCCAGCAGACCA-3′,
hCAT-1 anti-sense: 5′-TGTTCACAATTAGCCCAGAG-3′, eNOS sense: 5′-
CCAGCTAGCCAAAGTCACCAT-3′, eNOS anti-sense: 5′-GTCTCGGAGC-
CATACAGGATT-3′, IR-A sense: 5′-GCTGAAGCTGCCCTCGAGGA-3′, IR-
A anti-sense: 5′-CGAGATGGCCTGGGGACGAA-3′, IR-B sense: 5′-GCTG-
AAGCTGCCCTCGAGGA-3′, IR-B anti-sense 5′-AGATGGCCTAGGGTCC-
TCGG-3′, 28S sense: 5′-TTGAAAATCCGGGGGAGAG-3′, 28S anti-sense:
5′-ACATTGTTCCAACATGCCAG-3′. Expected size products were hCAT-
1 148 bp, eNOS 354 bp, IR-A 210 bp, IR-B 244 bp, and 28S 100 bp.
2.9. Intracellular NO determination
Intracellular NO was determined using the ﬂuorescent dye DAF-FM.
Conﬂuent cells grown on 100 mm2 culture plate were incubated in the
absence or presence of insulin (1 nmol/L, 8 h) and exposed (45 min,
37 °C) to 10 μmol/L DAF-FM in PBS (37 °C, pH 7.4). The ﬂuorescence
(λexc/λem: 495/510 nm) was determined in a Sinergy 2 microplate
reader (Biotek, Winooski, VT, USA) [17].
2.10. NOS activity
NOS activity was assayed by quantiﬁcation of the intracellular
content of L-citrulline by high performance liquid chromatography in
conﬂuent HUVECs in the absence or presence of 100 μmol/L L-NAME,
as reported [17].
2.11. Human umbilical vein reactivity
Ring segments of 2-4 mm in length were dissected from human
umbilical veins in ice-cold PBS (pH 7.4, 4 °C). Vein rings were mounted
in a myograph (610M Multiwire Myograph System, Danish Myo
Technology A/S, Denmark) for isometric force measurements in a Krebs
physiological solution (mmol/L: 118.5 NaCl, 4.7 KCl, 25 NaHCO3, 1.2
MgSO4, 1.2 KH2PO4, 2.5 CaCl2, 5.5 D-glucose, 0.3 L-arginine, 37 °C,
pH 7.4). Vein rings were constantly bubbled with a mixture of 95% O2/
5% CO2. The optimal diameter for each vessel was adjusted through the
determination of the maximal active response evoked by 65 mmol/L
KCl [13]. Endothelium-dependent relaxation was evaluated as the
concentration-dependent response to CGRP (0.01− 100 nmol/L,
5 min) and insulin (0.01−1000 nmol/L, 5 min) in KCl-preconstricted
vessels. Experiments were performed in the absence or presence of
100 μmol/L L-NAME. Changes in isometric tension were recorded using
the software LabChart (LabChart 7 for Windows, ADInstruments, Aus-
tralia) coupled to a PowerLab (PowerLab 8/30 Data Acquisition
System, ADInstruments, Australia).
2.12. Statistical analysis
The sample size was estimated considering a power of 80% to detect
a diﬀerence between groups (on the basis of a two-sided alpha level of
0.05). Values for clinical parameters are given as mean ± S.D. For in
vitro assays the values were mean ± S.E.M., where n indicates number
of diﬀerent biological samples and corresponding cell cultures with 3–4
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replicates per experiment. Comparisons between two groups were
performed by means of Student's unpaired t-test and between more than
two groups by analysis of variance (ANOVA, two-ways). If the ANOVA
demonstrated a signiﬁcant interaction between variables, post hoc
analyses were performed by the multiple-comparison Bonferroni test.
The statistical software GraphPad InStat 3.1 and GraphPad Prism 7.0c
(GraphPad Software Inc., San Diego, CA, USA) was used for data ana-
lysis. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Study groups
Pregnancies were singleton, and pregnant women showed with si-
milar age and height, were normotensive, and with normal fasting
glycaemia at term (Table 1). The total gestational weight gain between
pre-pregnancy and term was 10 ± 1 kg in normal pregnancies,
8.9 ± 0.9 kg in GDMd pregnancies, and 9.9 ± 1.1 kg in GDMi preg-
nancies. Clinical parameters of newborns from the three study groups
did not show signiﬁcant diﬀerences.
3.2. L-Arginine transport kinetics
The vi for overall 100 μmol/L L-arginine transport was lineal up to
60 s in cells from normal, GDMd, or GDMi pregnancies without insulin
(Fig. 1A). Values for vi were higher in cells from GDMd and GDMi
compared with normal pregnancies (Table 2). Overall L-arginine
transport was semisaturable in cells without insulin from normal,
GDMd, or GDMi pregnancies (Fig. 1B), with KD values higher in GDMd
and GDMi compared with normal pregnancies (Table 2). After sub-
stracting the lineal, non-saturable transport component from overall
transport, the remaining L-arginine transport was saturable, best ﬁtted
by a single Michaelis-Menten equation (Fig. 1C), and lineal in an Eadie-
Hofstee plot (Fig. 1D). Saturable transport showed with higher Vmax in
cells from GDMd and GDMi compared with normal pregnancies. The
apparent Km values were not signiﬁcantly altered in cells from these
three study groups. However, the maximal transport capacity (Vmax/
Km) was higher in GDMd and GDMi when compared with normal
pregnancies (Table 2).
Insulin increased the vi and KD in cells from normal pregnancies, but
restored this parameter in GDMd and GDMi (Fig. 1E). Overall transport
in the presence of insulin was also semisaturable (Fig. 1F), and satur-
able transport showed higher Vmax and Vmax/Km, but unaltered Km
values in cells from normal pregnancies (Fig. 1G). GDMd and GDMi-
increased L-arginine transport was blocked by insulin. Eadie-Hofstee
plot of saturable data was lineal in cells treated with insulin from all
study groups (Fig. 1H).
3.3. hCAT-1 protein abundance and mRNA expression
In cells without insulin the hCAT-1 protein abundance was higher in
GDMd and GDMi compared with normal pregnancies (Fig. 2A). In-
cubation of cells with insulin, increased hCAT-1 protein abundance in
normal pregnancies, but partially reduced its abundance in GDMd and
GDMi. Similar results were obtained for hCAT-1 mRNA expression
without or with insulin; however, insulin fully reversed GDMd eﬀect
(Fig. 2B).
3.4. Involvement of p44/42mapk and Akt on L-arginine transport
Cells from GDMd and GDMi without insulin show increased p44/
42mapk phosphorylation compared with normal pregnancies (Fig. 3A).
Insulin blocked the GDMd and GDMi eﬀect, but increased p44/p42mapk
phosphorylation in cells from normal pregnancies. Phosphorylated Akt
protein abundance was unaltered by GDMd or GDMi, or insulin in cells
from normal or GDM pregnancies. IR-A mRNA expression was higher in
cells from GDMd and GDMi compared with normal pregnancies
(Fig. 3B). Insulin blocked GDM eﬀect on IR-A mRNA expression, but
unaltered its expression in cells from normal pregnancies. However, IR-
B mRNA expression was unaltered by GDM or insulin.
Table 1
Clinical characteristics of pregnant women and newborns.
Variable Normal (n= 13) GDMd (n= 14) GDMi (n= 18)
Mother
Age (years) 32.1 ± 3.8 33.7 ± 5.2 30.5 ± 4.5
Height (cm) 162.5 ± 4.3 157.6 ± 6.1 160.2 ± 4.4
Weight (kg)
Pre-pregnancy 62.8 ± 7.7 69.2 ± 9.3 72.2 ± 10.9⁎
1st trimester 63.3 ± 8.2 70.1 ± 9.6 72.5 ± 10.8⁎
2st trimester 67.4 ± 6.2 74.3 ± 7.9 79.2 ± 9.5⁎
3th trimester 73.7 ± 4.6 76.1 ± 8.8 81.0 ± 10.6
Term 73.8 ± 4.9 78.1 ± 4.1 82.1 ± 9.4⁎
BMI (kg/m2)
Pre-pregnancy 23.8 ± 2.5 26.9 ± 3.2 28.3 ± 3.9⁎
1st trimester 23.6 ± 2.7 27.8 ± 3.2⁎ 28.4 ± 4.1⁎
2nd trimester 25.4 ± 1.9 28.9 ± 3.1⁎ 31.1 ± 2.9⁎
3th trimester 28.1 ± 0.8 33.1 ± 2.8⁎ 31.4 ± 3.6⁎
Term 28.1 ± 1.4 33.4 ± 4.4⁎ 32.5 ± 3.1⁎
Systolic blood pressure
(mm Hg)
Pre-pregnancy 101.4 ± 6.9 113.9 ± 9.9 104.6 ± 6.3
1st trimester 106.9 ± 5.4 110.1 ± 11.1 106.7 ± 7.7
2nd trimester 105.7 ± 9.8 109.2 ± 9.2 105.4 ± 9.7
3th trimester 108.1 ± 7.5 109.6 ± 15.6 109.5 ± 11.7
Term 113.8 ± 5.2 110.4 ± 7.1 110.2 ± 10.6
Diastolic blood
pressure (mm Hg)
Pre-pregnancy 62.9 ± 4.9 70.7 ± 6.2 68.6 ± 6.3
1st trimester 67.7 ± 6.4 65.2 ± 9.1 66.4 ± 6.1
2nd trimester 67.1 ± 7.6 66.3 ± 8.5 65.7 ± 5.8
3th trimester 66.3 ± 5.8 69.2 ± 10.1 69.5 ± 7.7
Term 67.5 ± 8.9 72.2 ± 8.8 71.5 ± 5.1
Mean arterial pressure
(mm Hg)
Pre-pregnancy 75.7 ± 4.6 70.7 ± 6.2 80.6 ± 5.2
1st trimester 80.8 ± 3.9 81.8 ± 8.6 80.1 ± 5.6
2nd trimester 80.1 ± 7.2 81.9 ± 9.2 78.9 ± 6.7
3th trimester 80.2 ± 6.2 82.7 ± 11.8 82.8 ± 8.2
Term 82.9 ± 7.1 84.3 ± 7.1 84.4 ± 5.7
Glycemia fasting (mg/
dL)
82.9 ± 7.1 85.1 ± 4.9 87.8 ± 8.1
OGTT (mg/dL)
Glycemia basal 78.3 ± 5.1 85.8 ± 8.8 84.4 ± 15.3
Glycemia 2 h after
glucose
82.9 ± 7.1 155.5 ± 13.9⁎ 165.9 ± 20.1⁎
Newborn
Sex (female/male) 7/6 8/6 10/8
Gestational age (weeks) 38.5 ± 1.3 38.8 ± 0.6 38.4 ± 0.6
Birth weight (grams) 3374 ± 411 3441 ± 447 3552 ± 517
Height (cm) 50.2 ± 1.3 50.1 ± 1.5 50.1 ± 1.4
Ponderal index (grams/
cm3 × 100)
2.7 ± 0.3 2.7 ± 0.2 2.8 ± 0.3
Women that coursed with normal pregnancies (Normal), GDM under treatment with diet
(GDMd) or GDMd passed onto insulin therapy (GDMi) were included in this study.
Weight, body mass index (BMI), and blood pressure were determined before pregnancy
(pre-pregnancy) and at 1st (0–14 weeks of gestation (wg)), 2nd (14–28 wg) or 3th
(28–40 wg) trimesters of pregnancy and at term (38–41 wg). Values for pre-pregnancy
weight and blood pressure correspond to those autoreferred by patients. In Normal
pregnancies, 11 women were with pre-pregnancy normal weight (BMI< 25 kg/m2) and
two with pre-pregnancy overweight (BMI ≥25 and< 30 kg/m2). In GDMd, 11 women
were with pre-pregnancy normal weight, two pre-pregnancy overweight, and one pre-
pregnancy obese (BMI ≥30 kg/m2). In GDMi, 14 women were with pre-pregnancy
normal weight, two pre-pregnancy overweight, and two pre-pregnancy obese. BMI was
calculated by weight in kilograms divided by the square of the height in meters. Ponderal
index was calculated by weight in grams divided by the cube of height in centimeters
multiplied by 100. Oral glucose tolerance test (OGTT) was measured at 24–28 weeks of
gestation in all women with a normal glycaemia (see Material and methods).
Values are mean ± S.D.
⁎ P < 0.05 versus corresponding values in Normal.
M. Subiabre et al. BBA - Molecular Basis of Disease 1863 (2017) 2987–2998
2990
Fig. 1. L-Arginine transport in HUVECs from GDMi pregnancies. A. Initial velocity of 100 μmol/L L-arginine uptake at various times in HUVECs from normal, gestational diabetes on diet
(GMDd), and GDMd into insulin therapy (GDMi) without exogenous insulin in vitro. Straight dashed lines represent the lineal phase of uptake estimated for 0.5 s incubation (see Material
and methods). B. Overall L-arginine transport measured at initial velocity ﬁtted to a single Michaelis-Menten equation increased in a lineal component (see Material and methods). C.
Saturable L-arginine transport derived from data in B adjusted to a single Michaelis-Menten equation. D. Eadie-Hofstee representation of data in C. E to H are cells in the presence (8 h) of
1 nmol/L insulin (with insulin). *P < 0.05 versus corresponding values in GDMi or GDMd. For some data points the error bars were smaller than the symbols. Values are mean ± S.E.M.
(n= 7–11).
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Overall L-arginine transport in the presence of PD-98059 and Inh-IV
was semisaturable as in the absence of these inhibitors (not shown).
Incubation of cells with PD-98059, Inh-IV, or both, did not alter the vi
or KD values in cells from normal pregnancies without insulin (Table 2).
However, insulin-stimulatory eﬀect on these parameters was blocked
by PD-98059 or PD-98059 + Inh-IV, but unaltered by Inh-IV alone.
Insulin-increased Vmax and Vmax/Km for saturable transport was blocked
by PD-98059 or PD-98059 + Inh-IV; however, Inh-IV alone blocked the
increase caused by insulin in the Vmax/Km, but not in Vmax (Fig. 3C,
Table 2). In cells without insulin the GDMd-increased vi and Vmax were
blocked only by PD-98059 or PD-98059 + Inh-IV. The GDMd-increased
Vmax/Km was blocked by PD-98059, Inh-IV, or PD-98059 + Inh-IV.
However, incubation of cells with PD-98059 or PD-98059 + Inh-IV, but
not with Inh-IV alone, resulted in higher KD values compared with cells
from GDMd in the absence of these inhibitors (Table 2). Insulin reversed
the increase caused by GDMd in all the kinetic parameters in the ab-
sence or presence of inhibitors. However, KD values in cells with insulin
and inhibitors were unaltered compared with cells without insulin in
the presence of the inhibitors. The inhibitors caused a similar pattern of
inhibition in cells from GDMi without insulin, except for cells incubated
with PD-98059 where KD value was unaltered compared with cells in
the absence of this inhibitor (Table 2). In cells with insulin the pattern
of eﬀects of the inhibitors in the kinetic parameters was similar com-
pared to those in cells from GDMd, except for Inh-IV which inhibits the
increase in vi caused by GDMi.
3.5. NOS activity
The intracellular content of L-citrulline generated by NOS activity
(i.e., fraction inhibited by L-NAME) was higher reaching similar values
in cells from GDMi and GDMd, compared with normal pregnancies
(Fig. 4A). Insulin caused a substantial reduction in GDM-increased L-
citrulline content, but increased intracellular content of this amino acid
in cells from normal pregnancies. In addition, the NO level detected in
cells from GDMd and GDMi was higher than normal pregnancies
(Fig. 4B). Insulin increased NO level in cells from normal pregnancies,
and partially reversed the eﬀect of GDM.
Table 2
Kinetic parameters for L-arginine transport in HUVECs from normal or GDM pregnancies.
Saturable transport Overall transport
Vmax (pmol/μg protein/
minute)
Km (μmol/L) Vmax/Km (pmol/μg protein/minute/
(μmol/L))
KD (pmol/μg protein/minute/(μmol/
L))
vi (pmol/μg protein/0.5 s)
Normal pregnancies (n= 13)
Without insulin
Control 0.50 ± 0.06 144 ± 55 0.0035 ± 0.0009 0.00012 ± 0.0001 0.00171 ± 0.00021
PD-98059 0.60 ± 0.07 197 ± 59 0.0030 ± 0.0006 0.00014 ± 0.0001 0.00168 ± 0.00017
Inh-IV 0.45 ± 0.07 123 ± 71 0.0037 ± 0.0013 0.00015 ± 0.0003 0.00168 ± 0.00031
PD-98059 + Inh-IV 0.53 ± 0.05 274 ± 58 0.0019 ± 0.0003 0.00012 ± 0.0001 0.00118 ± 0.00009
With insulin
Control 0.89 ± 0.07⁎ 164 ± 42 0.0054 ± 0.0009⁎ 0.00044 ± 0.0001⁎ 0.00281 ± 0.00023⁎
PD-98059 0.62 ± 0.09⁎⁎ 223 ± 90 0.0028 ± 0.0008⁎⁎ 0.00012 ± 0.0001⁎⁎ 0.00159 ± 0.00021⁎⁎
Inh-IV 0.63 ± 0.03⁎⁎ 123 ± 15 0.0051 ± 0.0004⁎ 0.00040 ± 0.0001⁎ 0.00235 ± 0.00010⁎
PD-98059 + Inh-IV 0.46 ± 0.03⁎⁎ 258 ± 40 0.0030 ± 0.0009⁎⁎ 0.00024 ± 0.0001⁎⁎ 0.00107 ± 0.00005⁎⁎
GDMd pregnancies (n= 14)
Without insulin
Control 1.61 ± 0.14⁎ 269 ± 61 0.0060 ± 0.0009⁎ 0.00046 ± 0.0001⁎ 0.00363 ± 0.00028⁎
PD-98059 0.65 ± 0.07⁎⁎ 143 ± 51 0.0045 ± 0.0010⁎⁎ 0.00092 ± 0.0003⁎,⁎⁎ 0.00223 ± 0.00025⁎⁎
Inh-IV 1.44 ± 0.20⁎ 295 ± 96 0.0049 ± 0.0012⁎ 0.00040 ± 0.0001⁎ 0.00303 ± 0.00035⁎
PD-98059 + Inh-IV 0.93 ± 0.09⁎⁎ 211 ± 53 0.0044 ± 0.0005⁎⁎ 0.00080 ± 0.0002⁎,⁎⁎ 0.00249 ± 0.00021⁎⁎
With insulin
Control 0.61 ± 0.03⁎⁎⁎ 141 ± 24 0.0042 ± 0.0005‡ 0.00019 ± 0.0001‡ 0.00210 ± 0.00028‡
PD-98059 0.83 ± 0.04⁎⁎⁎ 210 ± 27 0.0039 ± 0.0004⁎⁎⁎ 0.00096 ± 0.0001⁎,⁎⁎⁎ 0.00227 ± 0.00023⁎⁎⁎
Inh-IV 0.49 ± 0.03⁎⁎⁎ 159 ± 23 0.0031 ± 0.0003⁎⁎⁎ 0.00040 ± 0.0001⁎,⁎⁎⁎ 0.00298 ± 0.00025⁎
PD-98059 + Inh-IV 0.73 ± 0.07⁎⁎⁎ 144 ± 45 0.0051 ± 0.0010⁎⁎⁎ 0.00114 ± 0.0003⁎,⁎⁎⁎ 0.00208 ± 0.00026⁎⁎⁎
GDMi pregnancies (n= 18)
Without insulin
Control 1.28 ± 0.07⁎ 213 ± 32 0.0060 ± 0.0006⁎ 0.00066 ± 0.0003⁎ 0.00340 ± 0.00017⁎
PD-98059 0.92 ± 0.14⁎⁎ 223 ± 75 0.0041 ± 0.0009⁎⁎ 0.00056 ± 0.0001⁎ 0.00237 ± 0.00028⁎⁎
Inh-IV 1.48 ± 0.09⁎ 254 ± 40 0.0058 ± 0.0007⁎ 0.00022 ± 0.0001⁎,⁎⁎ 0.00348 ± 0.00018⁎
PD-98059 + Inh-IV 0.63 ± 0.08⁎⁎ 164 ± 60 0.0038 ± 0.0009⁎⁎ 0.00102 ± 0.0010⁎,⁎⁎ 0.00198 ± 0.00024⁎⁎
With insulin
Control 0.51 ± 0.03⁎⁎⁎ 111 ± 17 0.0046 ± 0.0005⁎⁎⁎ 0.00024 ± 0.0003⁎⁎⁎ 0.00201 ± 0.00010⁎⁎⁎
PD-98059 0.46 ± 0.03⁎⁎⁎ 108 ± 24 0.0043 ± 0.0006⁎⁎⁎ 0.00120 ± 0.0010⁎,⁎⁎⁎ 0.00184 ± 0.00013⁎⁎⁎
Inh-IV 0.54 ± 0.03⁎⁎⁎ 193 ± 29 0.0028 ± 0.0003‡ 0.00036 ± 0.0001⁎,⁎⁎⁎ 0.00153 ± 0.00007⁎⁎⁎
PD-98059 + Inh-IV 0.62 ± 0.09⁎⁎⁎ 218 ± 93 0.0028 ± 0.0014⁎⁎⁎ 0.00130 ± 0.0010⁎,⁎⁎⁎ 0.00162 ± 0.00023⁎⁎⁎
L-Arginine transport (0–1000 μmo/L, 1 min, 37 °C) was measured in HUVECs from normal pregnancies (Normal), GDM under treatment with diet (GDMd) or GDMd passed onto insulin
therapy (GDMi) exposed (8 h) to culture medium without (Without insulin) or with (With insulin) insulin (1 nmol/L). Transport assays were done in the absence (Control) or presence of the
PD- 98059 (10 μmol/L, MEK1/2 inhibitor) and Akt Inhibitor IV (Inh-IV, 1 μmol/L) or both (see Material and methods). Maximal velocity (Vmax) and apparent Michaelis-Menten constant
(Km) of saturable transport were calculated assuming a single Michaelis-Menten hyperbola. Vmax/Km represents maximal L-arginine transport capacity. The lineal phase of overall
transport of L-arginine (KD) was obtained from transport data ﬁtted to a Michaelis-Menten equation increased in a lineal component. Initial velocity (vi) was calculated for 0.5 s with
100 μmol/L L-arginine transport.
Values are mean ± S.E.M.
⁎ P < 0.05 versus corresponding Control values in Normal Without insulin.
⁎⁎ P < 0.05 versus corresponding Control values.
⁎⁎⁎ P < 0.05 versus corresponding Control values Without insulin.
M. Subiabre et al. BBA - Molecular Basis of Disease 1863 (2017) 2987–2998
2992
3.6. eNOS expression and phosphorylation
Cells from GDMd and GDMi without insulin show comparable
higher eNOS protein abundance compared with normal pregnancies
(Fig. 4C). Insulin partially reduced GDM eﬀect on eNOS, but increased
its protein abundance in cells from normal pregnancies. In cells without
insulin the P-Ser1177 eNOS protein abundance was higher in GDM
pregnancies reaching similar values, an eﬀect blocked by insulin in cells
from GDMd, but partially reversed by this hormone in GDMi (Fig. 4D).
Insulin increased P-Ser1177 eNOS protein abundance in cells from
normal pregnancies. However, neither GDM nor insulin altered P-
Thr496 eNOS protein abundance (Fig. 4E). GDMd and GDMi associated
with higher and comparable eNOS mRNA expression (Fig. 4F) com-
pared with cells from normal pregnancies. Insulin reversed the GDM
eﬀect on eNOS mRNA, but increased mRNA expression in cells from
normal pregnancies.
3.7. Umbilical vein reactivity
Insulin caused concentration, NOS-dependent relaxation in umbi-
lical vein rings (Fig. 5A). Maximal relaxation (Rmax) in response to in-
sulin was lower, but half-maximal eﬀect (EC50) was higher in vein rings
from GDMd and GDMi compared with normal pregnancies (Table 3).
The required insulin concentration to cause a similar Rmax (i.e., EC50/
Rmax) was higher in GDMd and GDMi compared with normal preg-
nancies. The EC50/Rmax was higher in GDMi compared with vessel rings
from GDMd. CGRP also caused concentration-dependent relaxation of
vein rings (Fig. 5B) with an EC50 values lower than those for insulin
eﬀect in vessel rings from all conditions (Table 3). The EC50 in vein
rings from GDMd was lower than vessel rings from normal or GDMi
pregnancies, but higher in samples from GDMi (Table 3). The Rmax in
response to CGRP was similar than in response to insulin in normal
pregnancies. The EC50/Rmax values for CGRP were higher in GDMd and
GDMi compared with normal pregnancies, higher in GDMi compared
with GDMd pregnancies. In addition, the EC50/Rmax values for CGRP
were higher for vessel rings from all pregnancies.
4. Discussion
This study shows for the ﬁrst time that HUVECs from pregnancies
where the mother with GDMd was subjected to insulin therapy (GDMi)
exhibit increased L-arginine transport and NO synthesis, which was
comparable to cells from GDMd without insulin therapy or from normal
pregnancies exposed to insulin in vitro. Cells from GDMi show increased
p44/42mapk activation and IR-A mRNA expressiom, but unaltered Akt
activation and IR-B expression. Insulin in vitro reversed GDMi eﬀect on
L-arginine transport, NO synthesis and p44/42mapk activation. NO and
endothelium-dependent dilation of umbilical vein rings from GDMi was
reduced in response to insulin compared with GDMd or normal preg-
nancies. Mothers and newborns from GDMi showed with normogly-
caemia at term, but insulin therapy seems not enough to restore asso-
ciated foetoplacental vascular dysfunction.
GDM associates with reduced foetoplacental vascular reactivity due
to microvascular [26] and macrovascular [12,13,16] endothelial dys-
function [5,6]. HUVECs from women with GDMd (i.e., without insulin
therapy) show increased L-arginine transport mediated by hCAT-1 [13]
and NO synthesis due to eNOS activation [16] compared with normal
pregnancies. Incubation of HUVECs from GDMd with insulin in vitro
reversed the increased transport of L-arginine (half-maximal eﬀective
dose (ED50) ~0.3 nmol/L) [27] and NO synthesis (ED50 ~0.4 nmol/L)
[12] seen in this condition. Our results show that HUVECs from GDMi
pregnancies exhibit similar changes to those in GDMd pregnancies.
Thus, insulin therapy does not restores GDMd-associated human um-
bilical vein endothelial dysfunction. L-Arginine transport is mainly
mediated by hCAT-1 with an apparent Km ~100–200 μmol/L in HU-
VECs from normal pregnancies [28–30], a value close to the con-
centration of this amino acid in the human umbilical vein blood
(~80 μmol/L) [31,32]. Thus, hCAT-1 plays a crucial role in the uptake
of L-arginine in HUVECs. Saturable L-arginine transport in HUVECs
from GDMi, and GDMd pregnancies shows apparent Km within hCAT-1
range. Furthermore, hCAT-1 protein and mRNA expression were higher
in HUVECs from GDMi and GDMd compared with normal pregnancies.
Thus, hCAT-1 is likely involved in the removal of L-arginine from the
extracellular medium, and GDMi or GDMd unaltered this membrane
transporter’s intrinsic properties. hCAT-2B, another member of hCATs
family [14,15], is coexpressed with hCAT-1 in HUVECs [33] mediating
L-arginine transport with Km ~300–400 μmol/L [14,15]. Therefore,
hCAT-2B may also mediate L-arginine transport in HUVECs from GDMi
pregnancies. However, since Eadie-Hofstee plot of saturable transport
and overall transport up to 250 μmol/L L-arginine were lineal, it is
likely that a single membrane transport system in the range of
100–200 μmol/L (likely hCAT-1), or more than one transport system
with Km within this range, accounted for uptake of L-arginine into
HUVECs. hCAT-1 involvement on GDMi and GDMd-increased transport
is further supported by the results showing that hCAT-1 protein abun-
dance and mRNA expression was higher (~5 fold) in cells from GDMi
and GDMd compared with normal pregnancies. Thus, increased L-ar-
ginine transport may result from higher hCAT-1 availability in HUVECs.
Since the Vmax increase in GDMi and GDMd versus normal pregnancies
was ~2.6 and ~3.2 fold, respectively, and because these conditions
Fig. 2. hCAT-1 expression in HUVECs from GDMi pregnancies. A. Western blot for hCAT-
1 and β-actin (internal reference) protein abundance in HUVECs from normal, gestational
diabetes on diet (GMDd), and GDMd into insulin therapy (GDMi) without or with (8 h)
exogenous insulin in vitro. Lower panel: hCAT-1/β-actin ratio densitometries normalized to
1 in Normal. B. hCAT-1 mRNA expression as in A. *P < 0.05 versus Normal Without
insulin. †P < 0.05 versus corresponding values Without insulin. Values are
mean ± S.E.M. (n= 5).
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caused similar increase in hCAT-1 expression, a fraction not larger than
36–50% may be due to a change in hCAT-1 expression or availability at
the plasma membrane in HUVECs from GDMi and GDMd.
The Vmax and Vmax/Km values in GDMi were similar to those in
GDMd pregnancies, but higher compared with normal pregnancies.
Thus, insulin therapy does not result in reversal of hCAT-1–mediated
maximal transport capacity in HUVECs from GDM pregnancies. Since
the increase in Vmax/Km was similar in GDMi and GDMd, but GDMi
caused lower increase in Vmax compared with GDMd (GDMi Vmax/GDMd
Vmax ~0.7), diﬀerent component(s) to those in GDMd may modulate L-
arginine transport in cells from GDMi pregnancies. Interestingly, overall
L-arginine transport for values> 250 μmol/L showed higher KD for
GDMi compared with GDMd (~1.43 fold) and normal pregnancies
(~5.5 fold). Thus, along with hCAT-1, L-arginine uptake seems medi-
ated via a transport system(s) that does not gets saturated up to
1000 μmol/L in cells from GDMi and GDMd pregnancies. Since ap-
parent Km for hCAT-3, member of hCATs family [14,15], is> 500
μmol/L [34], these transporters may be involved in overall L-arginine
transport playing a minor contribution at< 250 μmol/L L-arginine in
HUVECs.
Phosphorylation of p44/42mapk was increased, but Akt phosphor-
ylation was unaltered in cells from GDMi compared with normal
pregnancies or in HUVECs from women with GDM not separated by diet
only versus diet plus insulin therapy (GDMpool) [28]. Since GDMi and
GDMd-increased L-arginine transport was reversed by inhibiting p44/
42mapk, but unaltered by Akt inhibition, increased transport may result
from p44/42mapk activation. This is likely in cells from GDMi, but may
only partially explain the GDMd increase in transport (increased p44/
42mapk phosphorylation/increased transport ~0.53). It is likely that
increased IR-A expression accounts for GDMi eﬀects since activation or
overexpression of this type of insulin receptors results in preferential
activation of p44/42mapk (i.e., p44/42mapk activation/Akt activa-
tion> 1) in HUVECs [5,12,16]. All together these ﬁndings highlight
potential diﬀerences on L-arginine transport modulation in HUVECs
from these two conditions of pregnancy. Previous studies show in-
creased eNOS activity in HUVECs from GDMpool [28,35] or GDMd [16]
pregnancies compared with normal pregnancies. We extended these
observations to GDMi pregnancies where higher NO level and NOS
activity was found, a phenomenon likely due to higher activator Ser1177
phosphorylation of eNOS [36,37]. Since eNOS protein abundance and
mRNA expression were also increased in cells from these conditions,
increased eNOS expression, reduced degradation or increased stability
of eNOS protein or mRNA are alternative mechanisms that may be in-
volved in this phenomenon.
Insulin restored the Vmax/Km of transport by reducing the Vmax in
cells from GDMi to values in normal pregnancies, conﬁrming previous
results in cells from GDMpool [28] or GDMd [13] pregnancies. Since the
Km was not changed by insulin, it is likely hCAT-1 aﬃnity for L-arginine
uptake is unaltered by this hormone in cells from GDMi pregnancies.
However, since GDMi-increased KD and vi was reversed by insulin, this
hormone may restore the functionality of an alternative mechanism,
potentially hCAT-3, for L-arginine transport. Since insulin also restored
Fig. 3. Involvement of p44/42mapk and Akt on L-arginine transport in HUVECs from GDMi pregnancies. A. Western blot for total (Total p44/42mapk) and phosphorylated (P-p44/42mapk)
p44/42mapk, and total (Total Akt) and phosphorylated (P-Akt) Akt, and β-actin (internal reference) protein abundance in HUVECs from normal, gestational diabetes on diet (GMDd), and
GDMd into insulin therapy (GDMi) without or with (8 h) exogenous insulin in vitro. Lower panels: P-p44/42mapk/total p44/42mapk or P-Akt/total Akt ratio densitometries normalized to 1
in Normal Without insulin. B. Insulin receptor A (IR-A) and B (IR-B) mRNA expression in HUVECs as in A. C. Saturable L-arginine transport measured at initial velocity adjusted to a single
Michaelis-Menten equation in cells incubated in the presence of PD-98059 (10 μmol/L), Akt Inhibitor IV (Inh-IV, 1 μmol/L), or both, without or with insulin (1 nmol/L). Saturable L-
arginine transport in cells in the absence of insulin and inhibitors (Controls, red dotted lines) or presence of insulin (Insulin, 1 nmol/L, blue dotted lines) from Fig. 1C and G are shown.
*P < 0.05 versus Normal Without insulin. †P < 0.05 versus corresponding values Without insulin. Values are mean ± S.E.M. (n= 5).
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Fig. 4. Nitric oxide synthesis in HUVECs from GDMi pregnancies. A. L-Citrulline synthesis was measured by h.p.l.c. (see Material and methods) in HUVECs from normal, gestational
diabetes on diet (GMDd), and GDMd into insulin therapy (GDMi) incubated without or with exogenous insulin (1 nmol/L, 8 h) in vitro in the absence or presence of NG-nitro-L-arginine
methyl ester (L-NAME, 100 μmol/L). Lower panel: L-citrulline synthesis via nitric oxide synthase (NOS) activity derived from data in A. B. Relative ﬂuorescence units (RFU) were measured
in cells preloaded with the ﬂuorescent dye 4-amino-5-methylamino-2′,7′-diﬂuorescein (DAF-FM, 10 μmol/L) as in A. Lower panel: nitric oxide (NO) generation via NOS activity derived
from data in B. C. Western blot for total eNOS (Total eNOS), eNOS phosphorylated at serine1177 (P-Ser1177-eNOS) or threonine495 (P-Thr495-eNOS) and β-actin (internal reference) protein
abundance as in A. The graph shows Total eNOS/β-actin ratio densitometries normalized to 1 in Normal Without insulin. D. P-Ser1177-eNOS/total eNOS ratio densitometries normalized
to 1 in Normal Without insulin from data in C. E. P-Thr495-eNOS/total eNOS ratio densitometries normalized to 1 in Normal Without insulin from data in C. F. eNOS mRNA expression as
in A. *P < 0.05 versus Normal Without insulin. †P < 0.05 versus corresponding values Without insulin. Values are mean ± S.E.M. (n= 5).
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GDMi-increased hCAT-1 expression, this hormone may regulate hCAT-1
bioavailability in HUVECs from GDMi pregnancies. The contribution of
a reduced hCAT-1 protein abundance to the lower Vmax/Km for trans-
port caused by insulin in GDMi is partial since not more than two-thirds
reduction in transport could be explained by changes in hCAT-1 protein
abundance [(reduced Vmax/Km) / (reduced hCAT-1)− 1 is ~0.65].
However, in GDMd the reduced Vmax/Km could be explained by similar
reduction in hCAT-1 protein abundance. Insulin-reduced hCAT-1 mRNA
expression (~60%) was similar to this transporter’s protein abundance
in GDMi pregnancies. Since insulin-restoration of GDMd-increased hC-
AT-1 mediated transport in HUVECs resulted from lower protein
abundance due to lower transcription of SLC7A1 gene (for hCAT-1)
[13], insulin restoration of GDMi-increased hCAT-1 mediated transport
may result from a similar phenomenon.
Inhibition of p44/42mapk restores GDMi- and GDMd-increased L-
arginine transport in the same proportion as insulin. Thus, p44/42mapk
over-activation could be responsible for these pathological conditions’s
associated increased transport, complementing similar results in cells
from normal pregnancies in response to insulin [28,33]. Insulin also
activates insulin receptor A (IR-A) that mediates preferential activation
of p44/42mapk compared with Akt (p44/42mapk/Akt > 1), and insulin
receptor B (IR-B) mediating preferential Akt activation compared with
p44/42mapk (p44/42mapk/Akt < 1) in HUVECs [16]. Since HUVECs
from GDMi in the absence of exogenous insulin show p44/42mapk/Akt
~1.7, a value close to the increase in Vmax/Km, IR-A signalling is likely
increased in GDMi. Indeed, IR-A, but not IR-B mRNA expression is
higher in cells from GDMi compared with normal pregnancies, and is
similar to the increase seen in GDMd, as reported [12,16]. Since insulin
restored p44/42mapk/Akt in cells from GDMi, and GDMi-increased IR-A
mRNA is reversed to values in normal pregnancies, insulin beneﬁcial
eﬀect on L-arginine transport, NO synthesis and eNOS expression and
activation in HUVECs from GDMi was likely due to restoring IR-A ex-
pression and its associated cell signalling. A likely functional con-
sequence of the described alterations caused by GDM at a cellular level,
is a lower response of umbilical vessels to insulin. The results show that
required insulin to generate a NO-dependent dilation of these vessels
[(NormalEC50/Rmax) / (GDMiEC50/Rmax)] was higher in GDMi (~18 fold)
and GDMd (~13 fold), compared with vessel rings from normal preg-
nancies. This phenomenon could result from a lack of endothelial
function since the response of vessels to CGRP was also reduced in
GDMi (~10 fold). However, GDMi would be a stronger condition than
GDMd generating endothelial dysfunction since CGRP response to in-
sulin was ~7 fold higher than in GDMd.
In conclusion, HUVECs from GDMi pregnancies show increased L-
arginine transport and NO synthesis, and reduced vascular reactivity
compared with normal pregnancies. These ﬁndings are comparable to
those in GDMd, suggesting that insulin therapy in pregnancy does not
resolve the foetoplacental endothelial dysfunction associated with GDM
pregnancies. However, since we used primary cultures of HUVECs and
umbilical vein rings in vitro, our conclusions should not be taken as
categorical. Insulin therapy normalizes maternal and foetal glycaemia
[9,18,19], but nothing is reported regarding the potential eﬀect of this
intervention on foetus wellbeing [3,5]. Insulin therapy associates with
higher frequency of complications in neonates [38], including larger
chance to be born large for gestational age [39], larger number (~25%)
of infants with one or more episodes with neonatal morbidity (neonatal
asymptomatic hypoglycaemia) [40], and polyhydramnios [41], com-
pared with infants born to mothers with GDMd. Since maternal insulin
therapy eﬀect in foetus development, newborn, and postnatal altera-
tions are still unclear [3,5,9,42], maternal and neonatal complications
are comparable in GDMi and GDMd [19,39], and insulin therapy seems
not to revert GDM-associated foetoplacental endothelial dysfunction,
Fig. 5. Human umbilical vein dilation in GDMi pregnancies. A. Human umbilical vein
rings isolated from normal, gestational diabetes on diet (GMDd), and GDMd into insulin
therapy (GDMi) were incubated without (0) or with exogenous insulin in the absence or
presence of NG-nitro-L-arginine methyl ester (L-NAME, 100 μmol/L). B. Vein rings re-
sponse to calcitonin gene related protein (CGRP) as in A. *P < 0.05 versus corre-
sponding values in GDMi or GDMd. Values are mean ± S.E.M. (n= 3–6).
Table 3
Vasodilation parameters in human umbilical vein rings.
Normal (n= 13) GDMd (n= 14) GDMi (n= 18)
Insulin
EC50 (nmol/
L)
1.39 ± 0.05 6.95 ± 0.31⁎ 12.3 ± 0.71⁎,⁎⁎
Rmax (%) 38 ± 6 14 ± 2⁎ 18 ± 3⁎
EC50/Rmax
(a.u.)
0.037 ± 0.005 0.496 ±0.005⁎ 0.682 ± 0.007⁎,⁎⁎
CGRP
EC50 (nmol/
L)
0.37 ± 0.02⁎⁎⁎ 0.20 ± 0.03⁎,⁎⁎⁎ 1.62 ± 0.31⁎,⁎⁎,⁎⁎⁎
Rmax (%) 29 ± 5 12 ± 4* 14 ± 3*
EC50/Rmax
(a.u.)
0.013 ± 0.001⁎⁎⁎ 0.017 ± 0.003⁎,⁎⁎⁎ 0.121 ± 0.002⁎,⁎⁎,⁎⁎⁎
Human umbilical vein rings were obtained from cords from normal pregnancies
(Normal), GDM under treatment with diet (GDMd) or GDMd passed onto insulin therapy
(GDMi). Vein rings were preconstricted with 65 mmol/L KCl and incubated with in-
creasing concentrations of insulin (0.01–1000 nmol/L) or calcitonin gene related protein
(CGRP) (0.01–100 nmol/L) in the absence or presence of NG-nitro-L-arginine methyl ester
(L-NAME, 100 μmol/L). Half-maximal eﬀective concentration (EC50) and maximal re-
laxation (Rmax) were calculated for the diﬀerence in insulin and CGRP response in the
absence or presence of L-NAME (i.e., nitric oxide synthase (NOS)-dependent relative re-
sponse).
Values are mean ± S.E.M.
a.u., arbitrary units.
⁎ P < 0.05 versus corresponding values in Normal.
⁎⁎ P < 0.05 versus corresponding values in GDMd.
⁎⁎⁎ P < 0.05 versus corresponding values in the presence of Insulin.
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subjecting pregnant women with GDM to insulin therapy should be
taken with caution since the risk of foetal health alterations.
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